A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study
Alzheimer’s disease (AD) is an age-related disease caused by abnormal accumulation of amyloid-β in the brain leading to progressive tissue degeneration. Flurbiprofen (FP), a drug used to mitigate the disease progression, has low efficacy due to its limited permeability across the blood–brain barrier...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Nanomaterials |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-4991/10/8/1590 |
id |
doaj-8e4ffc7241b24915a2961003a65d103f |
---|---|
record_format |
Article |
spelling |
doaj-8e4ffc7241b24915a2961003a65d103f2020-11-25T03:20:49ZengMDPI AGNanomaterials2079-49912020-08-01101590159010.3390/nano10081590A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro StudyShafq Al-azzawi0Dhafir Masheta1Anna Guildford2Gary Phillips3Matteo Santin4Centre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKCentre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKCentre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKCentre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKCentre for Regenerative Medicine and Devices, School of Pharmacy and Bimolecular Sciences, University of Brighton, Brighton BN2 4GJ, UKAlzheimer’s disease (AD) is an age-related disease caused by abnormal accumulation of amyloid-β in the brain leading to progressive tissue degeneration. Flurbiprofen (FP), a drug used to mitigate the disease progression, has low efficacy due to its limited permeability across the blood–brain barrier (BBB). In a previous work, FP was coupled at the uppermost branching of an ε-lysine-based branched carrier, its root presenting a phenylalanine moiety able to increase the hydrophobicity of the complex and enhance the transport across the BBB by adsorptive-mediated transcytosis (AMT). The present study explores a different molecular design of the FP-peptide delivery system, whereby its root presents an ApoE-mimicking peptide, a targeting ligand that could enhance transport across the BBB by receptor-mediated transcytosis (RMT). The functionalised complex was synthesised using a solid-phase peptide synthesis and characterised by mass spectrometry and FTIR. Cytotoxicity and permeability of this complex across an in vitro BBB model were analysed. Moreover, its activity and degradation to release the drug were investigated. The results revealed successful synthesis and grafting of FP molecules at the uppermost molecular branches of the lysine terminal without observed cytotoxicity. When covalently linked to the nanocarrier, FP was still active on target cells, albeit with a reduced activity, and was released as a free drug upon hydrolysis in a lysosome-mimicking medium. Noticeably, this work shows the high efficiency of RMT-driven FP delivery over delivery systems relying on AMT.https://www.mdpi.com/2079-4991/10/8/1590Alzheimer’s diseaseneurodegenerative diseasesblood–brain barrierApoE-peptidedrug delivery systemflurbiprofen |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shafq Al-azzawi Dhafir Masheta Anna Guildford Gary Phillips Matteo Santin |
spellingShingle |
Shafq Al-azzawi Dhafir Masheta Anna Guildford Gary Phillips Matteo Santin A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study Nanomaterials Alzheimer’s disease neurodegenerative diseases blood–brain barrier ApoE-peptide drug delivery system flurbiprofen |
author_facet |
Shafq Al-azzawi Dhafir Masheta Anna Guildford Gary Phillips Matteo Santin |
author_sort |
Shafq Al-azzawi |
title |
A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study |
title_short |
A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study |
title_full |
A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study |
title_fullStr |
A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study |
title_full_unstemmed |
A Peptide-Based Nanocarrier for an Enhanced Delivery and Targeting of Flurbiprofen into the Brain for the Treatment of Alzheimer’s Disease: An In Vitro Study |
title_sort |
peptide-based nanocarrier for an enhanced delivery and targeting of flurbiprofen into the brain for the treatment of alzheimer’s disease: an in vitro study |
publisher |
MDPI AG |
series |
Nanomaterials |
issn |
2079-4991 |
publishDate |
2020-08-01 |
description |
Alzheimer’s disease (AD) is an age-related disease caused by abnormal accumulation of amyloid-β in the brain leading to progressive tissue degeneration. Flurbiprofen (FP), a drug used to mitigate the disease progression, has low efficacy due to its limited permeability across the blood–brain barrier (BBB). In a previous work, FP was coupled at the uppermost branching of an ε-lysine-based branched carrier, its root presenting a phenylalanine moiety able to increase the hydrophobicity of the complex and enhance the transport across the BBB by adsorptive-mediated transcytosis (AMT). The present study explores a different molecular design of the FP-peptide delivery system, whereby its root presents an ApoE-mimicking peptide, a targeting ligand that could enhance transport across the BBB by receptor-mediated transcytosis (RMT). The functionalised complex was synthesised using a solid-phase peptide synthesis and characterised by mass spectrometry and FTIR. Cytotoxicity and permeability of this complex across an in vitro BBB model were analysed. Moreover, its activity and degradation to release the drug were investigated. The results revealed successful synthesis and grafting of FP molecules at the uppermost molecular branches of the lysine terminal without observed cytotoxicity. When covalently linked to the nanocarrier, FP was still active on target cells, albeit with a reduced activity, and was released as a free drug upon hydrolysis in a lysosome-mimicking medium. Noticeably, this work shows the high efficiency of RMT-driven FP delivery over delivery systems relying on AMT. |
topic |
Alzheimer’s disease neurodegenerative diseases blood–brain barrier ApoE-peptide drug delivery system flurbiprofen |
url |
https://www.mdpi.com/2079-4991/10/8/1590 |
work_keys_str_mv |
AT shafqalazzawi apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT dhafirmasheta apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT annaguildford apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT garyphillips apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT matteosantin apeptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT shafqalazzawi peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT dhafirmasheta peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT annaguildford peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT garyphillips peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy AT matteosantin peptidebasednanocarrierforanenhanceddeliveryandtargetingofflurbiprofenintothebrainforthetreatmentofalzheimersdiseaseaninvitrostudy |
_version_ |
1724616475409383424 |